Latest Von Willebrand disease Stories
CSL Behring Continues Improving Patient Well-Being; Key Milestone Achieved in PROLONG-9FP, Company's Recombinant Factor IX Fusion Protein Development Program KING OF PRUSSIA,
SAN FRANCISCO, December 7, 2014 /PRNewswire/ -- Today, Novo Nordisk announced a new analysis of phase 3 data demonstrating people with haemophilia A who had the highest
Twice-Weekly Prophylactic Regimen Resulted in 95% Reduction in Median Annualized Bleed Rate Compared to On-Demand Treatment SAN FRANCISCO, Dec.
PLAINSBORO, N.J., Dec.
FLINT, Mich., Nov. 4, 2014 /PRNewswire/ -- American Homecare Federation, a Diplomat company (NYSE: DPLO), is celebrating 25 years of business this year.
JNC is the Bleeding Disorders Community's Original Golf and Baseball Competition for Kids with Hemophilia and/or von Willebrand disease (VWD) and Their Families PHOENIX, Oct.
- Three-year findings regarding prophylaxis versus on-demand treatment in adults with hemophilia A WHIPPANY, N.J., Sept.
Twice-Weekly Prophylactic Regimen Resulted in 95% Reduction in Median Annualized Bleed Rate Compared to On-Demand DEERFIELD, Ill., Aug.
- Kogenate® FS antihemophilic factor (recombinant) approved for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults with hemophilia A WHIPPANY,
Data showing improved pharmacokinetic profile to be presented at World Federation of Hemophilia Congress MELBOURNE, Australia, May 11, 2014 /PRNewswire/ -- Interim Phase II/III and
- The word or words serving to define another word or expression, as in a dictionary entry.